Evidence map›Paper›PMID 40444259›Full record

ArticleCurrent rheumatology research2021

Chikungunya: an emerging rheumatological pandemic?

Joshua B Bilsborrow, J Kennedy Amaral, Robert Schoen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current rheumatology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Development and Application of Treatment for Chikungunya Fever.Research and reports in tropical medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joshua B BilsborrowSection of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States.
J Kennedy AmaralDepartment of Infectious Diseases and Tropical Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Robert SchoenSection of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States.

Funding

TRAINING PROGRAM IN INVESTIGATIVE RHEUMATOLOGYT32AR007107 · NIAMS · YALE UNIVERSITY · PI RICHARD J BUCALA · 1986 to 2026
$7.5M
NIAMS NIH HHS T32 AR007107
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) has recently emerged alongside Ebolavirus, Zika virus, and SARS-CoV-2 as the causative pathogen for a global pandemic. CHIKV is a single-stranded RNA alphavirus that is transmitted by

Indexed as

AlphavirusArthritisChikungunyaCOVID-19EpidemicPandemicVaccination

Identifiers

PMID40444259
PMCPMC12120434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.